The financials
Vir Biotechnology, Inc. by the numbers
For the full year FY2025, revenue was $69M (−7.6% year on year) and net income −$438M. Its largest product in 2025-Q2 was Contract at $1.5M, 89% of the disclosed total, just ahead of Grant at 11%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | n/a | $3.0M | n/a |
| Gross profit | n/a | $3.0M | n/a |
| Operating income | −$132M | −$140M | n/a |
| Net income | −$126M | −$121M | n/a |
| Diluted EPS | −$0.85 | −$0.88 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Contract | $1.5M | 89% |
| Grant | $183K | 11% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total −$29.0K (-112%)
Grant grew -99% year on yearOther -100% year on year
Segment Latestquarter on quarteryear on year
- Grant$12.0K$12.0KQoQ -96%year on year -99%-96%-99%
- Collaboration--QoQ -year on year ---
- Contract--QoQ -year on year ---
- Other$0.00$0.00QoQ -year on year -100%--100%
- License And Collaboration−$41.0K−$41.0KQoQ -year on year ---